India's Lupin falls on fears of market share loss for respiratory drug in US

** Shares of Indian drugmaker Lupin LUPIN down as much as 7.3% at 1,591.20 rupees; logs biggest intra-day pct drop since Feb. 2023

** U.S.-based Amphastar Pharmaceuticals AMPH said on Wednesday it got FDA Approval for Albuterol Sulfate Inhalation Aerosol used in treating respiratory ailments

** Lupin has 23.4% market share for the drug in U.S.

** Market reacting as one of LUPN's key product is now being priced for easy competition, said Shrikant Akolkar, pharma analyst at Nuvama Institutional Equities

** Going forward, Albuterol will not contribute as much as it used to contribute in FY23 or FY24, because the product has already seen some pricing pressure - Akolkar

** LUPN up 23% YTD vs 7.3% gains in BSE 100 (.BSE100) and 13% gains in pharma index CNXPHARMA